As mentioned above, the DESTINY-Gastric01 study also included patients with HER2 IHC 2+ and ISH-negative or IHC 1+ (of note, the IHC scoring system is different to that of breast cancer) gastric cancer. This evidence concerns the gene ERBB2 and breast cancer.